The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma

Liu, Liting; Tang, Lin‐Quan; Chen, Qiuyan; Zhang, Lu; Guo, Shan-Shan; Guo, Ling; Mo, Hao‐Yuan; Zhao, Chong; Guo, Xiang; Cao, Kejiang; Qian, Chao‐Nan; Zeng, Mu‐Sheng; Bei, Jin‐Xin; Hong, Ming; Shao, Jian Yong; Sun, Ying; Ma, Jingfei; Mai, Hai‐Qiang

doi:10.1016/j.ijrobp.2015.08.003

Cited by 123 publications

(123 citation statements)

References 33 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…Age, smoking history, EBV-DNA load, HB, GTVnx, and T and N classification as well as clinical stage have been reported to have a prognostic role in primary NPC patients in previous studies5254555657. In our study, age 50 was chosen to be the cut-off value according to previous studies on NPC patients as reported by Chen et al 54…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load

Zhou

Shi

Miao

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

Programmed death-1 (PD-1) is an immunosuppressive receptor functionally bound with programmed death-ligand 1 (PD-L1), which has been reported in various malignancies. However, only a few studies are available for the clinical significance of PD-1/PD-L1 in nasopharyngeal carcinoma (NPC). In this study, we aim to investigate alterations in PD-1/PD-L1 by using immunohistochemistry analysis in a cohort of consecutively enrolled NPC patients (n = 99). To further analyse the correlation between PD-1/PD-L1 and factors involved in clinico-pathology, haematologic biomarkers, EBV-DNA load and outcomes, we collected clinical data for statistical analysis. We observed that lower haemoglobin (HB) and Body Mass Index (BMI) levels were associated with high levels of PD-L1 staining in NPC patients. Importantly, our results suggested that PD-L1 might be a negative indicator for NPC patients. In contrast, a correlation between the PD-1/PD-L1 level and EBV load was not identified. Moreover, PD-1 positivity was suggested to not be significantly correlated with clinical outcomes. Taken together, our results revealed that PD-L1 might be a potential prognostic biomarker for NPC patients. However, further studies are needed to clarify the underlying mechanism of EBV status in the immunosuppression process induced by the PD-1/PD-L1 axis.

show abstract

Section: Discussionmentioning

confidence: 98%

“…P values were marked as *P < 0.05, **P < 0.01, ***P < 0.001, indicating different level of significance. These statistical analyses were performed with SPSS 16.0 484950515253545556575859.…”

Section: Methodsmentioning

confidence: 99%

PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load

Zhou

Shi

Miao

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…In our study, 9% of patients had stable disease after three cycles of TPF IC. Liu et al [17] found that an unsatisfactory tumor response (stable disease or disease progression) or detectable EBV DNA levels after IC were predictors of poor prognosis for patients with locoregionally advanced NPC. In a prospective study of children and young adults with NPC, the radiation dose during CCRT was decreased to 54 Gy in patients who achieved complete remission and 59.4 Gy in those who achieved partial remission after three cycles of IC; after a median follow-up of 30 months, none of these patients experienced locoregional recurrence [18].…”

Section: Main Textmentioning

confidence: 99%

Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma

Li¹,

Chen²,

Sun³

et al. 2016

Chin J Cancer

Self Cite

View full text Add to dashboard Cite

The value of adding induction chemotherapy (IC) to concurrent chemoradiotherapy (CCRT) for the treatment of locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear. In our recent article entitled “Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial” published in the Lancet Oncology, we reported the results of a phase III, multicenter, randomized controlled trial comparing cisplatin, 5-fluorouracil, and docetaxel (TPF) IC plus CCRT versus CCRT alone in patients with T3-4N1/TxN2-3M0 NPC (ClinicalTrials.gov registration number NCT01245959). The IC-plus-CCRT group showed significantly higher 3-year failure-free survival, overall survival, and distant failure-free survival rates than the CCRT-alone group, with an acceptable toxicity profile. Our study suggests that adding TPF IC to CCRT could increase survival rates and reduce distant failure in patients with locoregionally advanced NPC. However, long-term follow-up is required to assess the eventual efficacy and toxicity of this strategy, and a more accurate method to determine prognosis is needed to enable better tailoring of treatment strategy for individual patients.

show abstract

“…Liu and al. revealed that the unsatisfactory tumor response after induction chemotherapy (stable disease or disease progression) could predict poor prognosis for patients with advanced-stage NPC (locoregional relapse-free survival,PFS) [23]. However ;an another trial concluded that the overall tumor response after induction chemotherapy was an independent prognostic factor for disease-free-survival , OS and locoregional recurrence free survival [24].…”

Section: Resultsmentioning

confidence: 99%

Complete Clinical Response after Induction Chemotherapy Followed by Chemoradiotherapy in Nasopharyngeal Carcinoma: Impact on Oncologic Outcomes

Letaief¹,

Berrazaga²,

Ayadi³

et al. 2017

Journal of Cancer science and Clinical Oncology

View full text Add to dashboard Cite

Objective: Concomitant chemoradiation (RCT) represents the standard of care for locally-advanced nasopharyngeal carcinoma (NPC).Nevertheless induction chemotherapy (IC) followed by RCT is currently an attractive approach. Some trials showed a survival benefit of this therapeutic strategy. The aim of this study was to analyze complete clinical response (CCR) after IC and to assess its impact on disease control and survival.

show abstract

The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma

Cited by 123 publications

References 33 publications

PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load

PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load

Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma

Complete Clinical Response after Induction Chemotherapy Followed by Chemoradiotherapy in Nasopharyngeal Carcinoma: Impact on Oncologic Outcomes

Contact Info

Product

Resources

About